Baker Jillian G, Hall Ian P, Hill Stephen J
Institute of Cell Signaling, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.
Mol Pharmacol. 2004 Apr;65(4):986-98. doi: 10.1124/mol.65.4.986.
Many clinically used drugs are G-protein-coupled receptor (GPCR) antagonists and are given long-term to prevent receptor activation by endogenous agonists. Most GPCR antagonists are considered to have little agonist efficacy of their own. However, many beta antagonists do stimulate very small beta(2) adrenoceptor-mediated cAMP responses, but these responses become substantial at the level of cAMP response element (CRE)-gene transcription. Here, we compared the temporal characteristics of these beta(2) adrenoceptor-mediated cAMP and CRE-gene transcription responses with ligands of differing agonist efficacy. Within a minute, full agonists (e.g., isoprenaline) stimulated large increases in intracellular and exported cAMP. Very weak partial agonists (e.g., alprenolol) did not increase intracellular cAMP (only stimulating a small export). However, all agonists (regardless of efficacy) stimulated an increase in CRE-gene transcription after a 2-h incubation. An initial 30-min continual stimulation was required to initiate the process of CRE-gene transcription for all ligands. Longer agonist incubations resulted in larger gene transcription responses in a proportional manner for both weak and full agonists alike, and this was despite the lack of intracellular cAMP detection for the weaker ligands. Thus, the major initiator for CRE-gene transcription was not cAMP concentration or total quantity generated but a sustained turnover of intracellular cAMP and hence sustained stimulation of CREB phosphorylation. Thus, long-acting agonists and long-term treatments with very weak partial agonists (including many drugs classified previously as antagonists based on traditional second-messenger assays, e.g., several clinically used "beta-blockers") may cause more substantial gene transcription than previously believed.
许多临床使用的药物是G蛋白偶联受体(GPCR)拮抗剂,长期使用以防止内源性激动剂激活受体。大多数GPCR拮抗剂被认为自身几乎没有激动剂效力。然而,许多β拮抗剂确实能刺激非常小的β2肾上腺素能受体介导的cAMP反应,但这些反应在cAMP反应元件(CRE)-基因转录水平上变得显著。在这里,我们比较了这些β2肾上腺素能受体介导的cAMP和CRE-基因转录反应与不同激动剂效力配体的时间特征。在一分钟内,完全激动剂(如异丙肾上腺素)刺激细胞内和分泌的cAMP大幅增加。非常弱的部分激动剂(如阿普洛尔)不会增加细胞内cAMP(仅刺激少量分泌)。然而,所有激动剂(无论效力如何)在孵育2小时后都能刺激CRE-基因转录增加。所有配体都需要最初30分钟的持续刺激来启动CRE-基因转录过程。对于弱激动剂和完全激动剂,更长时间的激动剂孵育都会以成比例的方式导致更大的基因转录反应,尽管较弱的配体未检测到细胞内cAMP。因此,CRE-基因转录的主要启动因素不是cAMP浓度或产生的总量,而是细胞内cAMP的持续周转,从而持续刺激CREB磷酸化。因此,长效激动剂和用非常弱的部分激动剂进行长期治疗(包括许多以前根据传统第二信使测定法归类为拮抗剂的药物,例如几种临床使用的“β阻滞剂”)可能会导致比以前认为的更显著 的基因转录。